RISK OF UPPER GASTROINTESTINAL (GI) TRACT EVENTS IN RISEDRONATE AND/OR ALENDRONATE USERS IN THE ERA OF MARKETED GENERIC ALENDRONATE PRODUCTS

被引：0
|
作者：
Ralston, S. H. [1 ]
Kou, T. D. [2 ]
Wick-Urban, B. C. [3 ]
Steinbuch, M. [2 ]
机构：
[1] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Procter & Gamble Pharmaceut Inc, Mason, OH USA
[3] Procter & Gamble Pharmaceut Inc, Schwalbach, Germany
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 28 条
  • [21] Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition
    Gomez Acotto, Claudia
    Antonelli, Carlos
    Flynn, Damien
    McDaid, Dennis
    Roldan, Emilio J. A.
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (05) : 325 - 334
  • [22] Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study
    Y.-L. Peng
    H.-Y. Hu
    J.-C. Luo
    M.-C. Hou
    H.-C. Lin
    F.-Y. Lee
    Osteoporosis International, 2014, 25 : 1617 - 1623
  • [23] Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study
    Peng, Y. -L.
    Hu, H. -Y.
    Luo, J. -C.
    Hou, M. -C.
    Lin, H. -C.
    Lee, F. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (05) : 1617 - 1623
  • [24] LOWER HIP FRACTURE RATES IN THE FIRST YEAR OF THERAPY TRANSLATE INTO FAVORABLE COST-EFFECTIVENESS FOR RISEDRONATE VS. GENERIC ALENDRONATE AMONG HIGH RISK PATIENTS
    Thompson, M. F.
    Pasquale, M. K.
    Grima, D. T.
    VALUE IN HEALTH, 2009, 12 (03) : A68 - A68
  • [25] Stratifying the risk of clinical upper GI events in NSAID users: Results from a double-blind outcomes study
    Laine, L
    Hawkey, CJ
    Bombardier, C
    Shapiro, D
    Reicin, A
    GASTROENTEROLOGY, 2001, 120 (05) : A105 - A105
  • [26] Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A population-based study
    Valkhoff, Vera E.
    van Soest, Eva M.
    Mazzaglia, Giampiero
    Molokhia, Mariam
    Schade, Rene
    Trifiro, Gianluca
    Goldstein, Jay L.
    Hernandez-Diaz, Sonia
    Kuipers, Ernst J.
    Sturkenboom, Miriam C. J. M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (08): : 2792 - 2802
  • [27] Serotonin selective reuptake inhibitors (SSRIs) are not associated with an increased risk of upper gastrointestinal events in users of non-steroidal anti-inflammatory drugs (NSAIDs)
    Targownik, Laura E.
    Metge, Colleen J.
    Leung, Stella
    GASTROENTEROLOGY, 2008, 134 (04) : A736 - A736
  • [28] ASGE Upper GI Tract: A Potpourri of AI, Imaging, Resection and Myotomy RISK OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICE: A NOVEL PREDICTION MODEL PROPOSAL USING SUPERVISED MACHINE LEARNING
    Mohan, Babu
    McEntire, Dan
    Kucharski, Kimberly
    Gow-Lee, Benjamin
    Ali, Hassam
    Fang, John
    GASTROINTESTINAL ENDOSCOPY, 2023, 97 (06) : AB1238 - AB1238
123